U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 8C9H10N4O4.7C4H10N2
Molecular Weight 2508.55
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACEFYLLINE PIPERAZINE

SMILES

C1CNCCN1.C2CNCCN2.C3CNCCN3.C4CNCCN4.C5CNCCN5.C6CNCCN6.C7CNCCN7.CN8C9=C(N(CC(O)=O)C=N9)C(=O)N(C)C8=O.CN%10C%11=C(N(CC(O)=O)C=N%11)C(=O)N(C)C%10=O.CN%12C%13=C(N(CC(O)=O)C=N%13)C(=O)N(C)C%12=O.CN%14C%15=C(N(CC(O)=O)C=N%15)C(=O)N(C)C%14=O.CN%16C%17=C(N(CC(O)=O)C=N%17)C(=O)N(C)C%16=O.CN%18C%19=C(N(CC(O)=O)C=N%19)C(=O)N(C)C%18=O.CN%20C%21=C(N(CC(O)=O)C=N%21)C(=O)N(C)C%20=O.CN%22C%23=C(N(CC(O)=O)C=N%23)C(=O)N(C)C%22=O

InChI

InChIKey=IUKJNIOSXCPLLP-UHFFFAOYSA-N
InChI=1S/8C9H10N4O4.7C4H10N2/c8*1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15;7*1-2-6-4-3-5-1/h8*4H,3H2,1-2H3,(H,14,15);7*5-6H,1-4H2

HIDE SMILES / InChI

Description

Acefylline is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. Acephylline piperazine is a theophylline derivative with a direct bronchodilator action. It has the advantages over theophylline in being far less toxic and producing minimal gastric irritation. It is indicated for the treatment of asthma, emphysema, acute and chronic bronchitis associated with bronchospasm.Acefylline relaxes smooth muscles, relieves bronchospasm & has a stimulant effect on respiration. It stimulates the myocardium & central nervous system, decreases peripheral resistance & venous pressure & causes diuresis. The mechanism of action is still not clear, inhibition of phosphodiesterase with a resulting increase in intracellular cyclic AMP does occur, but not apparently at concentrations normally used for clinical effect. Other proposed mechanisms of action include adenosine receptor antagonism, prostaglandin antagonism & effects on intracellular calcium. Sodium phenobarbital is a non-selective central nervous system depressant that is primarily used as sedative-hypnotic.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
27.6 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Etaphylline
Primary
Etaphylline
Primary
Etaphylline
Primary
Etaphylline

PubMed

Sample Use Guides

In Vivo Use Guide
Dosage & route of administration & duration: The optimum therapeutic serum concentration is considered to range from 10 to 20 mcg/ml To avoid adverse effects the rate of infusion administration should not exceed 20 mg / min For I.M & slow I.V injection of 200 mg over at least 15 min. For IV infusion a loading dose of 4 mg/kg may be given over 20 to 30 min followed by a suggested maintenance dose of 0.5 mg /kg / hour reduced after 12 hours to 0.4 mg/kg/hour. Suggested Doses for children: 4mg/Kg by slow IV injection over at least 15 min or by infusion with a loading dose of 4 mg/kg followed by maintenance doses of: Children from 6 months to 6 years...................0.8 to 1 mg/kg/hour, reduced after the first 12 hours to 0.6 mg/kg/hour. Children over 6 years.....................................0.75 mg/kg/hour, reduced after the first 12 hours to 0.5 mg/kg/hour.
Route of Administration: Parenteral
In Vitro Use Guide
After topical application of a gel formulation containing 3% acefylline at the surface of reconstructed human epidermis, immunoblotting analysis showed an increase in the total amount of deiminated proteins, and confocal microscopy showed an enhanced deimination in the stratum corneum. This demonstrated the activation of PADs in living cells.